Latest Content

Roswell Park Comprehensive Cancer Center researchers are investigating whether CAR T-cell therapy could target some of the most common autoimmune diseases.

Pirtobrutinib plus venetoclax and rituximab improved PFS in relapsed/refractory CLL/SLL, meeting the primary end point of BRUIN CLL-322.

Sofetabart mipitecan elicited strong antitumor activity in recurrent platinum-resistant high-grade serous ovarian cancer.

Ibrutinib given prior to apheresis was associated with improved outcomes with tisagenlecleucel vs post-apheresis administration in relapsed/refractory LBCL.

R. Lor Randall, MD, FACS, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases.

The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Single-agent rezatapopt showed efficacy and safety irrespective of platinum status, prior bevacizumab or PARP inhibitor exposure, or FRα expression.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.

Cadonilimab combined with chemotherapy demonstrated robust efficacy and a favorable safety profile in advanced or recurrent endometrial cancer.

Patients who received first-line niraparib as maintenance therapy had high resolution rates and low number of discontinuations due to hematologic PSEOIs.

A significant increase in treatment completion was observed among Black women with high-risk endometrial cancer who received 1:1 peer support.

Trastuzumab pamirtecan achieved ~50% ORR in pretreated HER2-expressing endometrial cancer, earning FDA breakthrough designation per phase 1/2 trial data.